Flyout Menu
donate
MEMBER login
Facebook-f Twitter Linkedin-in Instagram

Highlights from ADA 84th Scientific Sessions

Highlights from American Diabetes Association (ADA) 84th Scientific Sessions

Join us as we bring you the latest highlights from the American Diabetes Association (ADA) 84th Scientific Sessions in Orlando, FL, USA, taking place 21-24 June 2024!


Supported by an unrestricted educational grant from AstraZeneca, Lilly and Novo Nordisk.

Click on the tabs below to watch videos from the ADA 84th Scientific Sessions.

Highlight Videos

American Diabetes Association (ADA) Scientific Sessions

ADA Scientific Sessions - 2026

ADA Scientific Sessions - 2025

ADA Scientific Sessions - 2024

European Association for the Study of Diabetes (EASD) Annual Meeting

EASD Annual Meeting - 2025

Highlights from American Diabetes Association (ADA) 84th Scientific Sessions

Join us as we bring you the latest highlights from the American Diabetes Association (ADA) 84th Scientific Sessions in Orlando, FL, USA, taking place 21-24 June 2024!


Supported by an unrestricted educational grant from AstraZeneca, Lilly and Novo Nordisk.

Click on the tabs below to watch videos from the ADA 84th Scientific Sessions.

Sof Andrikopoulos

Welcome to ADA

Mark Cooper

Edwin Bierman Award Lecture—Diabetes and Cardiovascular Disease—The Evolution of CV Outcomes Assessment of Antihyperglycemic Medications

Helen Tesfaye

The Risk of Heart Failure Hospitalization after Initiation of SGLT2i, GLP-1RA, DPP-4i, or SUs in Patients with Type 2 Diabetes and Low-to-Moderate CV Risk

Roger Chen

SURMOUNT-OSA Trial Results and Potential Role of Tirzepatide in Treating Obesity-Related Obstructive Sleep Apnea

Mark Cooper

SGLT2 Inhibition Impact on Human Physiology

Ramzi Ajjan

CGM in Type 2 Diabetes – An Overview from the ADA

The ADS gratefully acknowledges the support from Lilly for the SURPASS-CVOT Trial videos.
David Nathan

Newly-Diagnosed Type 2 Diabetes – What Should Be the Focus of Management in 2024?

Steven Kahn

SELECT Trial – New Looks at Glycemia, Inflammation, and Heart Failure

André Gustavo Daher Vianna

Once Weekly Insulins – Data Presented at ADA

Jonathan Shaw

ADA Diabetes Care Symposium – The Final Frontier – Implementing the Learning from Implementation Science

Roger Chen

GLP-1 +/- GIP Receptor Agonists in the Perioperative Setting – To Stop or Not to Stop?

Jerry Greenfield

GLP-1 +/- GIP Receptor Agonists in the Perioperative Setting – To Stop or Not to Stop?

Jonathan Shaw

Health Care Policy and Diabetes – How to Improve Population Health from Multiple Perspectives

The ADS gratefully acknowledges the support from Lilly for the SURPASS-CVOT Trial videos.
Mikhail Kosiborod

THE STEP-HFpEF and STEP-HFpEF-DM Trials – Targeting Obesity to Treat Heart Failure

Beverly Tchang

Severe GLP-1RA Side Effects in Obesity Treatment – Fact or Fiction?

Ramzi Ajjan

New Technology – Equity and Access

Jerry Greenfield

Noninsulin Treatment for Type 1 Diabetes

Ramzi Ajjan

Systemic Medications for Diabetic Retinopathy – Protective and Risk Factors

Jennifer Snaith

Efficacy and Safety of Tirzepatide in Overweight and Obese Patients with Type 1 Diabetes

Ronald Ma

Heterogeneity of Diabetes – Pathophysiology to Global Considerations

The ADS gratefully acknowledges the support from Lilly for the SURPASS-CVOT Trial videos.
Vlado Perkovic

The First Dedicated Kidney Outcome Trial with a GLP-1 Receptor Agonist – Once-Weekly Semaglutide and the FLOW Trial Results

Dianna Magliano

Keeping Up with Hollywood – Who Should Be Prioritized for New Antiobesity Medications?

Jane Speight

Advances Towards Beta Cell Therapy as a Potential Cure for Type 1 Diabetes

Dughyun Choi

SURMOUNT-OSA Trial Results and Potential Role of Tirzepatide in Treating Obesity-Related Obstructive Sleep Apnea

Yong Ho Lee

SELECT Trial – New Looks at Glycemia, Inflammation, and Heart Failure

So-Hun Kim

THE STEP-HFpEF and STEP-HFpEF-DM Trials – Targeting Obesity to Treat Heart Failure

The ADS gratefully acknowledges the support from Lilly for the SURPASS-CVOT Trial videos.